# Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer

> **NCT02902484** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 14 (actual)

## Conditions studied

- Cancer of Pancreas

## Interventions

- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT02902484
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-07
- **Primary completion:** 2021-10-26
- **Final completion:** 2021-10-26
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** The study was terminated due to futility and lack of future funding
- **Last updated:** 2024-06-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02902484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02902484, "Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02902484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*